Table 1. Association of clinicopathological characteristics of NSCLC patients and Tenascin serum levels.
| All (n) | Tenascin-C high (n and %) | Tenascin-C low (n and %) | Significance (p) | ||
|---|---|---|---|---|---|
| Age (cut65) | <65 | 43 | 18 (42%) | 25 (58%) | |
| ≥ 65 | 60 | 25 (42%) | 35 (58%) | 1.000 | |
| Sex | Male | 70 | 31 44%) | 39 (58%) | |
| Female | 33 | 12 (36%) | 21 (64%) | 0.523 | |
| Asbestos exposition† | Yes | 5 | 2 (40%) | 3 (60%) | |
| No | 85 | 35 (41%) | 50 (59%) | 1.000 | |
| Nicotine abuse† | Yes | 15 | 5 (33 %) | 10 (67%) | |
| No | 76 | 32 (42%) | 44 (58%) | 0.579 | |
| Neoadjuvant Therapy† | Yes | 82 | 32 (39%) | 50 (61%) | |
| No | 11 | 6 (55%) | 5 (45%) | 0.347 | |
| Tumor size† | pT1+2 | 74 | 26 (35%) | 48 (65%) | |
| pT3+4 | 20 | 13 (65%) | 7 (35%) | 0.022 | |
| Lymph nodes† | pN0+N1 | 45 | 13 (29%) | 32 (71%) | |
| pN2+N3 | 50 | 26 (52%) | 24 (48%) | 0.036 | |
| Distant metastases† | M0 | 94 | 38 (40%) | 56 (60%) | |
| M1 | 8 | 4 (50%) | 4 (50%) | 1.000 | |
| Grading† | G1 and G2 | 41 | 16 (39%) | 25 (61%) | |
| G3 | 51 | 21 (41%) | 30 (59%) | 1.000 | |
| Cell type | Adeno | 39 | 13 | 26 | |
| Sqamous Cell | 37 | 21 | 16 | ||
| Large Cell | 12 | 6 | 6 | 0.115 | |
| Resection† | R0 | 68 | 25 (37%) | 43 (63%) | |
| R1 | 7 | 4 (57%) | 3 (43%) | 0.419 | |
| 30-day Mortality† | Yes | 10 | 3 (30%) | 7 (70%) | |
| No | 91 | 39 (43%) | 52 (57%) | 0.516 | |
| Adjuvant Therapy† | Yes | 42 | 17 (41%) | 25 (59%) | |
| No | 51 | 21 (41%) | 30 (59%) | 1.000 |
†
Due to the retrospective character of the study, numbers do not always add up to 103 patients.